Journal article
Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls
Breast cancer research and treatment, Vol.156(3), pp.567-576
04/2016
DOI: 10.1007/s10549-016-3773-4
PMCID: PMC5053395
PMID: 27075917
Abstract
While adverse medical sequelae are associated with breast cancer therapies, information on breast cancer impact on medication use is limited. Therefore, we compared medication use before and after diagnosis of early stage breast cancer to medication use in matched, cancer-free controls. Of 68,132 Women's Health Initiative participants, 3726 were diagnosed with breast cancer and, after exclusions, in 1731 breast cancer cases, medication use before and >3 years after diagnosis (mean 5.3 ± 2.1 SD) was compared to use in 1731 cancer-free matched controls on similar inventory dates. The medication category number at follow-up inventory was the primary study outcome. Medication category use (n, mean, SD) was comparable at baseline and significantly increased at follow-up in both cases (2.48 ± 1.66 vs. 4.15 ± 2.13, baseline vs follow-up, respectively, P < .0001) and controls (2.44 ± 1.67 vs. 3.95 ± 2.13, respectively, P < .0001), with clinically marginal but statistically significant additional medication category use by cases (0.20 ± 2.40, P < .0001). Tamoxifen users used somewhat more selected medication categories at follow-up assessment (mean 3.40 ± 1.89 vs. 3.21 ± 1.99, respectively, P = 0.05), while aromatase inhibitor users used more medication categories (mean 4.85 ± 2.10 vs. 4.44 ± 1.94, respectively, P = 0.02). No increase in medication category was seen in cases who were not current endocrine therapy users. Breast cancer survivors having only a clinically marginal increase in medication use compared to cancer-free controls. These findings highlight the importance of incorporation of control populations in studies of cancer survivorship.
Details
- Title: Subtitle
- Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls
- Creators
- Kathy Pan - Harbor–UCLA Medical CenterRowan T Chlebowski - The Lundquist InstituteMichael S Simon - The Barbara Ann Karmanos Cancer InstituteRoberta M Ray - Fred Hutch Cancer CenterJennifer Livaudais-Toman - University of California, San FranciscoShannon D Sullivan - MedStar Washington Hospital CenterMarcia L Stefanick - Stanford Health CareRobert B Wallace - University of IowaMeryl LeBoff - Harvard UniversityElizabeth Carhart Bluhm - Brigham and Women's HospitalElectra D Paskett - The Ohio State University
- Resource Type
- Journal article
- Publication Details
- Breast cancer research and treatment, Vol.156(3), pp.567-576
- DOI
- 10.1007/s10549-016-3773-4
- PMID
- 27075917
- PMCID
- PMC5053395
- NLM abbreviation
- Breast Cancer Res Treat
- ISSN
- 0167-6806
- eISSN
- 1573-7217
- Grant note
- N01WH32111 / WHI NIH HHS N01 WH032118 / WHI NIH HHS 32108-9 / PHS HHS UM1 CA173642 / NCI NIH HHS N01WH42107 / NHLBI NIH HHS 32105-6 / PHS HHS N01WH32119 / WHI NIH HHS N01WH24152 / WHI NIH HHS 42129-32 / PHS HHS 42107-26 / PHS HHS N01WH44221 / WHI NIH HHS 32118-32119 / PHS HHS P30 ES005605 / NIEHS NIH HHS 24152 / PHS HHS N01WH42129 / WHI NIH HHS N01WH32122 / WHI NIH HHS N01WH32108 / WHI NIH HHS 32122 / PHS HHS 32111-13 / PHS HHS 32115 / PHS HHS 44221 / PHS HHS 32100-2 / PHS HHS N01 WH032100 / WHI NIH HHS N01WH32105 / NHLBI NIH HHS N01WH22110 / WHI NIH HHS N01 WH32115 / WHI NIH HHS
- Language
- English
- Date published
- 04/2016
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984364443402771
Metrics
16 Record Views